ReviewBiology2022
Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis C Virus Infection.
Review in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- [Screening of Hepatitis C virus in blood donors over 11 years].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Seroprevalence of hepatitis C virus infection among individuals attending a private clinic in Luanda, Angola.BMC infectious diseases · 2026Article
- Evaluation of the hepatitis c virus screening program in the Marche Region (Italy): experience from the Pesaro-Urbino health authority.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Hepatitis C Virus Infection Induces Autoimmune Hypothyroidism with Potential Profound Metabolic Implications: A Cross-Sectional Study in a High-Prevalence Region.Metabolites · 2026Article
- European Code Against Cancer, 5th edition - cancer-causing infections and related interventions.Molecular oncology · 2026Review
- Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit.Thrombosis and haemostasis · 2025Article
- Impact of Direct-Acting Antivirals on Extrahepatic Manifestations in Chronic Hepatitis C: A Narrative Review with a Hermeneutic Approach.Healthcare (Basel, Switzerland) · 2025Review
- Autoimmune manifestations and direct-acting antiviral drugs in Egyptian patients with hepatitis C virus infection: A cohort study.The Journal of international medical research · 2025Article
- Directly acting antivirals improve insulin resistance in nondiabetic patients with hepatitis C: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Article
- A Real-World Analysis of the Population with Hepatitis C Virus Infection Affected by Type 2 Diabetes in Italy: Patients' Characteristics, Comorbidity Profiles and Treatment Patterns.Medicina (Kaunas, Lithuania) · 2025Article
- The HCV-Melanoma Paradox: First Multi-Cohort and Molecular Net-Work Analysis Reveals Lower Incidence but Worse Outcomes-Integrating Clinical, Real-World, and In Silico Data.Medicina (Kaunas, Lithuania) · 2024Article
- Renal Manifestations of Chronic Hepatitis C: A Review.Journal of clinical medicine · 2024Review
- Renal Findings in Patients with Thalassemia at Abdominal Ultrasound: Should We Still Talk about "Incidentalomas"? Results of a Long-Term Follow-Up.Diagnostics (Basel, Switzerland) · 2024Article
- Review
- Hepatitis C Epidemiology: Insights from a Comprehensive Cohort Study in ASST Melegnano and Martesana, Lombardia Region, Northern Italy.Pathogens (Basel, Switzerland) · 2024Observational
- Hepatitis C virus antibody seropositivity is associated with albuminuria but not peripheral artery disease in patients with type 2 diabetes.Scientific reports · 2024Article
- Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China.BMC infectious diseases · 2024Observational
- Therapeutic Potential of Rituximab in Managing Hepatitis C-Associated Cryoglobulinemic Vasculitis: A Systematic Review.Journal of clinical medicine · 2023Review
- Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland.Journal of clinical medicine · 2023Article
- Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) is a significant cause of chronic liver diseases worldwide and is associated with negative consequences, including cirrhosis, hepatic decompensation, hepatocellular carcinoma, and increased risk of mortality. In addition to liver-related morbidities, HCV is also associated with several extrahepatic manifestations, including mixed cryoglobulinemia, diabetes mellitus, cardiocerebrovascular disease, lymphoma, and autoimmune diseases. These non-liver-related complications of HCV increase the complexity of this disease and can contribute to the economic burden, morbidity, quality of life, and mortality throughout the world. Therefore, understanding how this virus can contribute to each extrahepatic manifestation is worth investigating. Currently, the advancement of HCV treatment with the advent of direct-acting anti-viral agents (DAAs) has led to a high cure rate as a result of sustained virologic response and tremendously reduced the burden of extrahepatic complications. However, HCV-associated extrahepatic manifestations remain a relevant concern, and this review aims to give an updated highlight of the prevalence, risk factors, associated burdens, and treatment options for these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.